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Summary A pilot study was undertaken to determine the feasibility of infusing 131I labelled monoclonal
antibodies (MoAbs) into either the cavity remaining after resection of malignant glioma or into glioma cysts.
Of the seven patients recruited into the study, two had cystic lesions and five resection cavities. Six of the
seven were treated after relapse from primary therapy. All patients apart from one, were given a single
injection of 131I conjugated to a MoAb (ERIC-1) recognising the human neural cell adhesion molecule
(NCAM). One patient received a further injection of
1 I-MoAb after regrowth of their disease. Phar-
macokinetic studies revealed that the MoAb remained predominantly in the tumour cavity with little leakage
into the systemic compartment. This resulted in a high calculated dose of radiation being delivered to the
tumour cells either lining or within close proximity to the cavity/cyst wall. In such a small study, it is not
possible to determine accurately response rates, but individual patient responses were observed. This, along with the low toxicity noted, demonstrates the feasibility of using '311-MoAbs in this way. With "3'I, radiation
dose is deposited in tissue to a depth of I mm from the source. The possibility of applying isotopes such as 9OYttrium which will irradiate tumour/tissue to a greater depth (6 mm) is discussed in context with the biology
of glioma infiltration into normal brain parenchyma.
The systemic use of monoclonal antibodies (MoAbs) as
delivery vehicles for the selective targeting of therapeutic
agents to malignant disease has been disappointing. This is
due, predominantly, to poor penetration and insufficient
accumulation of MoAb conjugates into solid tumour deposits
(Sands et al., 1988). In general, systemic administration of
radioimmunoconjugates has resulted in only approximately
0.001-0.01% of the injected material being taken up into
each gram of tumour (Kemshead et al., 1984). This is
independent of either the disease targeted or the MoAb used,
and is thought to be brought about by factors such as a high
tumour interstitial pressure, non-specific sequestration of
MoAb into the reticuloendothelial system and poor penetra-
tion of conjugates through the capillary endothelium (Jain,
1990; 1991).
The above problems have led to the clinical use of MoAb
conjugates in situations where tumour access is not a limita-
tion. Antibody conjugates have been successfully used for the
treatment of diffuse haematological disease and for instilla-
tion into body compartments containing malignant infiltrates
(Epenetos et al., 1987; Lashford et al., 1988). In this context,
we have concentrated on the intrathecal administration of
"'I-MoAb conjugates to patients with a variety of leptomen-
ingeal malignancies, including medulloblastoma, car-
cinomatous meningitis and CNS leukaemia/lymphoma
(Moseley et al., 1990; Pizer et al., 1991). Encouraging res-
ponses to therapy have been noted. However, the use of
MoAbs as delivery agents in this scenario is highly selective
and does not address the question of penetration into solid
tumour deposits.
One approach to overcoming this problem is to instil
directly the MoAb into the tumour, but this is only likely to
be of value in the absence of marked metastatic spread of
disease. Under these circumstances, the MoAb is being used
to hold the therapeutic agent in situ rather than delivering the
cytotoxic agent selectively to malignant cells. An ideal can-
didate for such an approach to therapy is malignant glioma,
which tends to be locally invasive rather than metastatic.
Current primary treatment involves surgery and external
beam irradiation, and yet the outlook remains bleak, with a
median survival for patients with Grade III/IV tumours of
approximately 45 weeks (range 21-61) (Steward, 1989). At
relapse, further surgical intervention is possible, but the use
of additional external beam radiotherapy is excluded due to
limiting radiation toxicity to normal brain. As a way of
localising radiation to the tumour bed, brachytherapy has
been given using either sealed radiation sources or isotope
colloids (Halperin et al., 1988).
Here, we describe the feasibility ofinjecting "'I-MoAb into
the tumour cavity of patients who have undergone surgery
for recurrent malignant glioma. In addition, as a proportion
of patients will present with either primary or recurrent
tumours that are essentially cystic, we have investigated the
potential of administering the radiolabelled MoAb directly
into a cyst cavity.
In the seven patients studied, one was given two
treatments, the second after further debulking surgery. Two
of the patients had cystic lesions and the others were given
"'I-MoAbs into resection cavities. Toxicity data are presented
along with the clearance kinetics of the isotope from the
injection site. Antibody retention within the tumour is pro-
longed, with corresponding low blood levels. Dosimetric
analysis of the data indicates that bone marrow toxicity is
unlikely to be dose limiting when "'I-MoAbs are
administered via this route. In addition, doses to tumour are
high in comparison to those achieved in therapeutic studies
using systemically administered radiolabelled antibodies.
Materials and methods
Antibody radiolabelling and quality control
The MoAb, ERIC-1, of the IgG, isotype was radiolabelled
with "'I using the lodogen technique to a specific activity of
185-555 MBqmg-' of protein (Fraker & Speck, 1978).
Antibodies were screened for bacterial and pyrogen con-
tamination. Other quality control studies undertaken
included determination of free iodine in the preparation by
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Trichloracetic acid precipitation (10%) and the detection of
aggregate formation by Fast Protein Liquid Chromatography
(FPLC) using a Superose 12 column. The immunoreactive
fraction of each MoAb preparation was determined using a
modified LINDMO assay with an excess of human brain
homogenate (Lindmo et al., 1984). Non-specific binding to
brain was determined using an isotype matched control
antibody and occasionally also confirmed by blockade of
"3'I-ERIC-1 binding with a gross excess of non-radiolabelled
antibody. Administration of '31-MoAb to patients was under-
taken within 6 h of conjugation to reduce the possibility of
radiolysis.
Patient selection, presentation and assessment
Local Ethical Committee approval and an Administration of
Radioactive Substances Advisory Committee (ARSAC)
Licence were obtained for these investigations. Two groups
of patients were eligible for study:
(i) Those with recurrent malignant glioma after debulk-
ing surgery.
(ii) Those with malignant gliomas that had failed to re-
spond to conventional therapies and had a major
cystic component to their tumour.
In each case, an Ommaya reservoir was inserted into either
the resection cavity or the cystic element of the tumour.
Patients received steroid (Dexamethasone 4 mgtds) and
anti-convulsant (Phenytoin 200 mgbd) cover for 3 days prior
to, and for 3 weeks after, administration of the radiolabelled
MoAb. For the same period, they also received a thyroid
blocking regimen of Liothyronin 80 jig daily, supersaturated
Potassium Iodide 10 dropsqds and Potassium Perchlorate
200 mgtds. Intravenous access was established prior to injec-
tion.
Before receiving their therapeutic administration, patients
were given a diagnostic injection of '31I-ERIC-1 introduced
into the cavity/cyst via the Ommaya reservoir. Three nuclear
medicine scans were taken over the following 5 days to
ensure that the tumour cavity/cyst had sealed and that the
radionuclide would not leak markedly into either the CSF or
the blood. This was confirmed by sequential blood sampling
and 24 h urine collection.
Therapeutic injections of '3'1-MoAb were given within 48 h
of completing the diagnostic study. The patient's general
condition and neurological status were closely monitored
following MoAb therapy. Blood samples were again taken at
regular intervals, and urine volumes were recorded and sam-
pled for every 24 h period. When appropriate, nuclear
medicine imaging was undertaken to determine distribution
of the radioimmunoconjugate. The patients remained in
isolation at the Radiotherapy Centre, Bristol, until the dose
rate at 1 metre from them fell below 15 gtSv h-'.
Pharmacokinetics and dosimetry calculations
Serial 1 ml blood samples were counted in an LKB gamma
scintillation counter and both effective and time-corrected
biological blood time-activity curves constructed. Blood
volume was calculated on the basis of 75 mlkg-' for men
and 70 mlkg-' for women.
Urine volume per 24 h was recorded and 1 ml samples
from each 24 h collection counted as above. The daily excre-
tion of radioisotope was calculated and from this the amount
of activity remaining in the body was determined both in real
terms (effective) and in relation to the amount administered
(time-corrected or biological).
Scintigraphic images of the head and whole body were
taken when the residual activity was low enough for the
patient to be imaged. This was variable from patient to
patient. Scintigraphy was undertaken with a Siemens nuclear
medicine camera using a high energy collimator with 300,000
counts accrued for each image. In addition, serial
measurements of radioactivity were taken from the patient's
head surface using a highly collimated external radiation
probe.
Equations for tumour clearance half-times were obtained
by exponential fitting of the relevant points using Cricket
Graph" software and an Apple MacintoshTM computer.
Activity time integrals (area under curve) for both tumour
and blood were calculated using the linear trapezoidal rule
up to the last sampling point. Exponential extrapolation to
infinity provided the final radiation component (MathCadTM
software, Apple MacintoshTM computer).
The Medical Internal Radiation Dosimetry scheme
(MIRD) was used to calculate doses to various organs. The
general form of the equation for the dose to a target organ
is:
D = AS(,,S).
where A =The area under the source time activity
curve.
and S(t,S) = A constant representing the mean dose per
unit of accumulated activity from a parti-
cular source to a particular target organ.
Values of S for a variety of different target and source
organs have been calculated for both penetrating (y) and
non-penetrating (1) radiation (MIRD, 1971).
Results
Immunocytochemistry and Immunoscintigraphy
The MoAb used in these studies, ERIC-1, recognises NCAM
expressed on all gliomas examined (n => 50), as well as both
normal neural and astrocytic elements within the brain
(Bourne et al., 1991). Radioimmunoscintigraphy with tracer
amounts of "3'I-ERIC-1 (37 MBq) showed that the conjugate
predominantly remained within the tumour cyst. This was
confirmed by blood and urine analysis. The diagnostic
studies broadly predicted the data obtained after administra-
tion of therapeutic amounts of '3'I-MoAb. Radioimmuno-
scintigraphy, 7 to 21 days after administration of the
therapeutic conjugate into the tumour cyst/resection cavity,
indicated that the MoAb predominantly remained where it
was administered and did not diffuse widely throughout the
brain (Figure 1). From the resolution of the scans, it is not
possible to determine to what degree the isotope had diffused
into the brain parenchyma adjacent to the tumour.
Toxicity
Patients entered into the study were given an escalating dose
of '31I-ERIC-l ranging from 1329-2193 MBq (Table I).
However, the order of patients presented in Table I does not
reflect the sequence of therapy administered due to a change
of study design (see below). In each case, radioimmunocon-
jugate consisted of mainly non-aggregated IgG, containing
less than 5% free iodine. The immunoreactive fraction
ranged between 61-80% (Table I).
Minimal toxicity was observed even following administra-
tion of 2193 MBq of radioimmunoconjugate (Table II).
Acute toxicity was manifest by a minor focal fit which occur-
red during administration (patient 1) and by exacerbation of
pre-existing raised intracranial pressure in patient 7. In both
instances, symptoms were easily controllable and they
resolved rapidly. Medium term toxicity was observed in two
patients (3 (first injection} and 7) and was thought to be
brought about by oedema occurring in and around the
tumour. This was readily reversed in patient 3 (first injection)
following administration of steroids. However, in patient 7
further surgery was necessary, 3 weeks after '311-MoAb
injection, to remove what appeared, upon histological
examination, to be predominantly necrotic tissue. Due to the
prolonged retention time of '31I-ERIC-1 in the tumour cyst/
cavity, it was decided to discontinue dose escalation above
2193 MBq, as at this level patients represented a significant146 V. PAPANASTASSIOU et al.
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Tumour Cavity showing the tube
leading from the Ommaya Reservoir
Figure 1 a, CT scan of patient with a resection cavity following surgical removal of a recurrent glioma. In this section, the tubing
of the Ommaya reservoir leads into the posterior rim of the resection cavity. b and c, Radio-imaging of glioma cavity 17 days after
administration of '3ll-ERIC-1. Binding remains localised to the tumour. The head is illustrated in each image using a cobalt
marker: b, Anterior posterior view; c, Lateral view.
Table I Details of patients receiving intratumoural/intracavity injection of '31I-MoAb
Quality control
Injected % Free % Immunoreactive
Patient Age Tumours activity (MBq) iodine Aggregates fraction (%)
Cystic lesions
1 56 Cystic astrocytoma (anaplastic) 1475 <1 1 61
2 63 Cystic oligodendroglioma (anaplastic) 1640 2 1 70
Tumour resections
3 (a) 52 Glioblastoma multiforme 1329 <1 2 63
3 (b) 52 Glioblastoma multiforme 1350 1 1 68
4 31 Anaplastic oligodendroglioma 1490 <1 3 66
5 63 Glioblastoma multiforme 1515 <1 3 80
6 13 Glioblastoma multifonne 1568 5 2 70
7 45 Glioblastoma multiforme 2193 5 1 72
'All had recurrent tumour apart from patient 1.
Table II Toxicity observed in patients receiving intratumoural/intracavity injection of '3'I-MoAb
Injected
activity
Patient (MBq) Acute toxicity Medium-term toxicity
Cystic lesions
1 1475 Minor focal fit during administration None
2 1640 None None
Tumour resections
3 (a) 1329 None Cerebral oedema at 4 weeksa
3 (b) 1350 Episodes of vomiting None
4 1490 None None
5 1515 None None
6 1568 None Not evaluableb
7 2193 Exacerbation of elevated ICPC Tumour necrosis and oedema
requiring further surgery at 3 weeks
aReadily responded to steroids. bDied 4 weeks post-therapy of tumour progression. cResponded to steroids and
Mannitol. ICP = Intracranial pressure.
radiation risk to both nursing and medical staff (see Discus- and 6), radioactivity within the head was determined using a
sion). highly collimated external probe (Figure 2). To reduce
exposure of staff to patients with high levels of '"'I in their
Pharmacokinetics tumour, an indirect approach to determining tumour
clearance was employed in the remaining patients. In all
Clearance from the tumour/cyst cavity was determined either patients, 24 h urine collections were obtained, along with
directly or indirectly. In three patients (1, 3 (first injection) whole body scintigrams which revealed no extracranial
c'3'I-MoAb FOR TREATMENT OF MALIGNANT GLIOMAS 147
sources of isotope accumulation. For patients 2, 3b, 4, 5 and
7 the activity in the tumour at a particular time was cal-
culated to be the administered dose minus the sum of the
activity detected uin the blood and urine, and that detected
elsewhere by immunoscintigraphy (taken to be 0). To
validate this methodology (patient 3a) the calculated activity
Patient 3a
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in the tumour was compared with that obtained by direct
counting and a high degree of concordance was observed
(Figure 2). The elimination rate constants calculated from
these clearance curves are 9.473 x 10-3h-' (probe) vs
9.828 x 10- h-' (excretion) respectively.
Clearance of 131I from the tumour cavity/cyst clearly fol-
lowed bi-exponential kinetics in some patients and mono-
exponential in others (Figure 3). The reasons underlying this
are not clear. With only two patients treated with cystic
lesions, it is not possible to determine if radionuclide intro-
duced into a cyst persists longer than when introduced into a
tumour cavity. For patient 3, considerable variations in
clearance rate from the cavity were noted for injections 1 and
2. Prolonged retention of antibody was noted after the
second injection as compared to the first. As the patient had
further surgery between the two MoAb administrations, the
resection cavities must be considered as separate entities. It is
probably the relative 'leakiness' of the first resection cavity
that resulted in a faster clearance of '31I-MoAb from the
site.
Blood clearance kinetics were obtained on all patients
apart from patient 6. Peak blood levels were again variable
ranging from 0.13-14.8% of the injected dose (mean 4.95,
median 3.47). Peak blood level times ranged from 9.25 to
147 h (mean 63, median 51 h). Again, no correlation between
blood levels, peak blood times and site of administration was
possibly due to small patient numbers (Figure 4).
Dosimetry
20 40 60 80 100 120 140 Whole body dose calculated assuming contributions
Time post injection (hours) from both blood (p and Zy radiation) and tumour (6 radiation)
~~ ~ ~ ~ ~ ~ ~ ~~ni,fK, I hv +r%+-l xxy,he%L I%r%At A^,,, ty, le "Ino l1l Figure 2 Validation of the method of using indirect determina-
tion of isotope levels in glioma cysts resection cavities. Com-
parison of data obtained by highly collimated external probe and
indirect counting as described in the Results sections. * = By
external probe; = By calculation.
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Other patients' data calculated from urine excretion, blood levels and whole body scans
Figure 3 Clearance of '3'I-ERIC-1 from glioma cysts resection cavities following intratumoral injection of 131I-ERIC-1. Data was
obtained either directly using a highly collimated external probe (*) or by indirect calculation as discussed in the Results
section.
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DWb = Abld X S(Wb+Wb) + Atum X S(wb+-tum)
where Abld and Atum = the areas under the blood and
tumour time activity curves
respectively.
S(wb*wb) = 2.60 x 10-6 Gy/MBq x h.
S(wb+tum) = 8.30 x 1-' Gy/MBq x h.
Whole body doses were low, ranging from 0.08-0.31 Gy
(mean 0.18) (Table III). In patient 6, the dose calculated was
only that from the tumour as no blood data was available. In
patients 1, 2, 3 and 7, over 85% of the whole body dose was
due to the y radiation from the tumour site as blood activity
was extremely low. In patients 5 and 4 the contribution of
activity from the blood represented 25 and 50% respectively
of the total whole body dose due to the high peak blood
levels and consequent lower activity in the tumour. Correct-
ing whole body dose for MBq of activity administered gave a
range from 7 x I0-5-l.9 x 10-4Gy/MBq (mean 1.1 x
10-4 Gy/MBq).
The bone marrow dose (Drbm) was calculated assuming
contributions from whole body (13 and y), red bone marrow
(due to its high blood content) (1 and Zy) and tumour (y):
Drbm = Abld X S(rbm+wb) + 0.3 x Abld X
S(rbm * rbm) + Atum X S(rbm*-tum)
where Abld and
S(rbm*-wb)
0.3
S(rbm*-rbm)
and S(rbm*-tum)
Atum = as defined above.
= 2.90 x 10-6 Gy/MBq x hr
= the proportion of total blood
volume estimated to be present
in bone marrow.
= 6.20 x 10-5 Gy/MBq x h.
= 4.58 x 10-5Gy/MBq x h.
Doses to bone marrow ranged from 0.07-0.51 Gy (mean
0.25). In all cases, the majority (>65%) of the dose to the
marrow was as a result of blood circulating activity. As
might be predicted from these calculated doses, no myelosup-
pression was noted in any of the individuals studied. Dose to
marrow per MBq of activity injected was less variable than
the overall doses, ranging from 5 x 10-5-2.6 x 10-4Gy/
MBq (mean 1.5 x 10-4). Values for patient 6 are an under-
estimate as no blood data is available.
The dose to normal brain (Dbr) was calculated as the sum
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of a 'self-dose' from blood contained within the brain (p and
X radiation) and a component from the tumours y radiation,
using the formula:
Dbrain=P X Ab1d X S(br-br) + Atum S(br+ tum).
where p =Proportion of total blood volume
estimated to be present in the brain
(33 ml/patient's blood volume).
S(br*br) = 1.04 x 10-4 Gy/MBq x h.
and S(br+tum) = 4.58 x l0-5 Gy/MBq x h.
The doses to brain ranged from 2.15-9.23 Gy (mean 5.20);
results expected from the prolonged retention of isotope in
the tumour cavity. The dose to brain was almost exclusively
delivered from emissions from the tumour site as blood
activity only contributed a maximum of 0.017 Gy to the
total. No difference in brain dose was apparent whether 131I
was delivered into either a cystic lesion or tumour resection
cavity. Dose per MBq of activity injected ranged from
1.44 x 10-3-5.56 x 10-4 Gy/MBq, with a mean of 3.23 x
l0-3.
Volumes of glioma cysts were calculated from CT scans. In
the case of patients having tumour resections, an approxima-
tion of the isotope volume of distribution was made from
radioimmunoscintigraphic images. In each instance, the
tumour was assumed to be spherical. Two estimates of dose
to tumour are given, assuming either no antibody binding or
100% binding. This approach was undertaken to show the
dose range that can be achieved with this type of therapy as
it is difficult to be certain of the degree of antibody binding
obtained in each case. The values presented here should,
therefore, only be taken as an estimate of the doses that can
be achieved via targeting '3'1 by direct injection into a
tumour/cystic lesion. For the purpose of this model, only the
P component of 131I was considered. The 7 component
delivered to the tumour will be similar to the whole brain
dose as calculated above.
The mean tumour dose to tissue within the R95 of 1311
(Dtum) is derived both from the activity bound to the
periphery and from a shell of R95 thickness of unbound
activity within the cavity. R95 is defined as the thickness of
tissue in which 95% of the 13 energy from '31I is deposited
(0.992mm).
* Patient 1
$ Patient 2
Patient 3a
- Patient 3b
Patient 4
--Y-- - Patient 5
- ~ - Patient 7
400
Time post injection (hours)
Figure 4 Determination of the levels of '3'I in the blood of patients following intratumoral/intracavity injection of '31I-ERIC-1.
1 ml blood samples were counted and the level of 31I expressed is the % of the injected activity in the blood compartment.31I-MoAb FOR TREATMENT OF MALIGNANT GLIOMAS 149
Table III Dose to whole body, bone marrow and whole brain following intratumoural/
intracavity injection of "1I-MoAb
Whole body dose Bone marrow dose Whole brain dose
Dose Dose Dose
Total Activity Total Activity Total Activity
Patient (Gy) (Gy/MBq) (Gy) (Gy/MBq) (Gy) (Gy/MBq)
Cystic lesions
1 0.15 1 x 10-4 0.16 1.1 x 10-4 4.20 2.85 x 10-3
2 0.31 1.9 x 10-4 0.25 1.5 x 10-4 9.23 5.6 x 10-3
Tumour resections
3 (a) 0.87 7 x 10-5 0.07 5 x 10-5 2.60 2.0 x 10-3
3 (b) 0.12 9 x 10-5 0.07 6 x 10-5 3.55 2.7 x 10-3
4 0.13 9 x 10-5 0.51 3.5 x 10-4 2.15 1.4 x 10-3
5 0.18 1.2 x 10-4 0.39 2.6 x 10-4 4.22 2.8 x 10-3
6a 0.25 1.7 x 10-4 0.06 4 x 10-5 8.03 5.1 x 10-3
7 0.26 1.2 x 10-4 0.26 1.2 x 10-4 7.62 3.5 x 10-3
aOnly the component from tumour as no blood data was available.
Dtum =f x Atun, X S(glioma-bound) + (1-P) X
F(Volume of source*/Volume of cavity) x
Atum x S(gfioma4.unbound)
where f =The fraction of antibody
bound to tumour.
S(glioma+bound)"* =3.297 x 10- Gy/MBq x h.
S(gljoma+unbound)*u = 1.039 x 10- Gy/MBq x h.
Volume of source depends on the R95 of '31I=
0.992 mm.
"S values quoted here have been calculated in
conjuntion with the Department of Medical
Physics, Frenchay Hospital.
Assuming a uniform distribution of '13I within the tumour/
cyst cavity (i.e. no antibody binding) estimates of tumour
dose ranged from 20 to 164 Gy (mean 51.2) (Table IV). This
was calculated to be between six and 25 times the dose
received by normal brain. Alternatively, if the ideal situation
of 100% antibody binding is achieved, tumour doses increase
markedly to between 856 and 4504Gy (mean 1843). Using
these figures, the tumour to normal brain ratio ranged from
187-564: 1. It must be remembered, however, that because of
the R95 of 13'I being relatively short, dose deposition resulting
from antibody binding will only affect tumour within 1 mm
of the isotope source.
Response data
Both patients with cystic lesions demonstrated a marked
reduction in their need for aspiration of cyst fluid. For
example, patient 1 needed weekly aspiration prior to therapy,
but following infusion of 13II-ERIC-l no further aspirations
were necessary for a period of 5 months. Patient 1 died 9
months from 131I-MoAb therapy and patient 2 remains alive
Table IV Dose to tumour
administered directly
with stable disease 10 months after receiving the conjugate.
Of the patients with recurrent tumours, patient 3 remained
asymptomatic for 5 months, although he underwent debulk-
ing surgery to reduce intracranial pressure 2 months after
receiving the conjugate. The resected material was extremely
necrotic but contained occasional viable tumour cells. He
subsequently received a further injection of '3II-MoAb and is
alive with progressive disease 8 months from treatment.
Patient 4 had a symptom free period of 5 months before
requiring additional therapy, whilst patient 5 remains disease
free 5 months from '31I-MoAb injection. Patients 6 and 7
died 1 and 2 months from treatment. Patient 6 died due to
tumour progression distant from the site of MoAb injec-
tion.
Discussion
The infusion of '3'I-MoAbs directly into either a tumour
resection cavity or cystic lesion is fundamentally different to
using an antibody as a targeting agent. In the former in-
stance, the antibody is used to hold the therapeutic agent in
place, rather than to deliver it to malignant cells throughout
the body. Our approach can therefore be regarded as a
'liquid phase brachytherapy'.
In this study, we have used a MoAb that recognises
NCAM expressed on all gliomas studied (n>50) as well as
both normal neural and glial cells (Bourne et al., 1991).
Binding is predominantly restricted to tumour, because
access to normal brain is limited. This is clearly the case, as
scintigraphy after MoAb administration shows that concen-
tration of isotope is confined to the injection site up to 3
weeks after administration of the conjugate (Figure 1). To
what degree the radiolabelled MoAb diffuses into normal
brain parenchyma adjacent to the tumour is unclear. Very
assuming either 0 or 100% binding of '3'I-MoAb
into either a tumour cavity or tumour cyst
Mean dose to tumour
Estimated Assuming 0% binding Assuming 100% binding
tumour Dose Dose
volume Total Activity Total Activity
Patient (cm3) (Gy) (Gy/MBq) (Gy) (Gy/MBq)
Cystic lesions
1 58 27 0.018 1451 0.98
2 94 36 0.022 1733 1.06
Tumour resections
3 (a) 47 20 0.015 1225 0.92
3 (b) 46 28 0.021 1071 0.79
4 30 26 0.017 856 0.57
5 46 34 0.022 1270 0.84
6 18 164 0.10 4504 2.87
7 38 75 0.034 2635 1.20150 V. PAPANASTASSIOU et al.
preliminary observations using SPECT indicate that diffusion
is limited to 0.5-1.0cm from the site of infusion, although
this needs further study. A small degree of diffusion is impor-
tant if this approach to therapy is to work, as it is clear that
whilst glioma cells usually do not grossly metastasise, they
can invade normal brain parenchyma adjacent to the tumour
edge.
The selection of a MoAb that cross reacts with tumour
and normal tissue was deliberate, as this should limit
diffusion to the immediate vicinity of the injection site.
Diffusion should be restricted by binding to a gross excess of
antigen expressed on normal brain infiltrated by or surround-
ing the tumour. Furthermore, this should create a localised
area bathed in 131I exposing any invading malignant cells to a
'crossfire' effect from the 13-emissions from the 131I attached
to the MoAb binding to normal neural elements. If a
'tumour specific' MoAb is used that only binds to a limited
number of malignant glial cells in the normal brain paren-
chyma, theoretically neither of these effects will occur.
The difference between instilling '1I-MoAbs into tumour
cavities/cysts and the use ofisotope colloid is that a degree of
targeting can be obtained through the use of a MoAb. Even
accepting the potential errors that occur in the calculation of
dose to tumour, it is clear that a major therapeutic advantage
can be conferred by binding 131I to tumour and adjacent
brain. This is predominantly due to the short path length of
"31I with an R95 of 0.992 mm. However, this also implies that
the mean doses reported for targeting in Table IV are only
going to be delivered to a rim of tumour approximately
1.0 mm thick. With '3'I as the isotope, diffusion becomes
critical so that the volume of tumour exposed to 1B radiation
is increased.
It is clear from the nature ofglioma development, that the
choice of "3'I for conjugation to the MoAb is far from ideal.
This isotope is a relatively short range P emitter that also has
a component. A higher energy pure 13 emitter such as 9Y is
theoretically a much better candidate for use in this situation
(Moi et al., 1990). We have refrained from the use of 90Y
because of concerns regarding myelosuppression seen in
other studies (Stewart et al., 1990; Vriesendorp et al., 1991).
To overcome this problem, we initiated laboratory studies on
the conjugation of 90Y to MoAb, through the use of macro-
cycles. However, in the light of the pharmacokinetics
revealed in this study, we believe a more simplistic approach
involving DTPA-MoAb conjugates as the carrier for 9Y
should be feasible. Blood levels ofisotope have been very low
and, as a consequence, if 90Y-MoAb conjugates behave in a
similar fashion to '"'I MoAbs, there should be little concern
with respect to damage to bone marrow. An alternative
isotope of interest for targeting could be 32p, another P
emitter with a longer half-life than 'Y. Difficulties in the
conjugation of 32P to MoAbs have recently been resolved,
although the stability of such constructs requires further
investigation.
With respect to '1I-MoAbs, myelosuppression is clearly
not going to be the primary toxicity of this approach to
therapy. Administration ofsingle doses of"3'I to patients will
be limited by concerns regarding exposure of nursing and
medical staff to patients with high levels of I'lI in their
tumours. For example, measurement of tumour dose by an
external probe resulted in staff receiving 4ISv per exposure
to the patient and this was the reason for changing our
method ofdetermining tumour clearance. In this respect, the
use of alternative radionuclides such as 90Y is also greatly
preferable.
Peak blood levels of'11I-MoAbs were clearly higher in two
patients (4 and 5) as compared to the other five. These
individuals received their tracer and therapy studies at
different times from surgery. Clearance from a tumour cavity does not, therefore, depend just on the area sealing rapidly after surgery. It is clear from the two MoAb administrations
to patient 3 that the patency of the tumour cavity is critical
to obtain retention of the antibody at the injection site. To
check this, all patients receive a tracer study with 131I-MoAb prior to therapy and we are now waiting a minimum of 3
weeks from surgery before instilling MoAbs into tumour
resection cavities.
Estimates of tumour dosimetry are dependent upon an
accurate determination of tumour volume and the degree of
MoAb binding occurring in each patient. Both of these
values are extremely difficult to measure and are prone to
considerable error. Whilst estimation of the volume of
tumour cysts can be made from CT scans in patients having
debulking surgery, the best estimate of cavity volume can be
made from nuclear medicine images. Here, one is determin-
ing the volume of isotope distribution which includes any
areas of localised diffusion that have taken place. Further-
more, to enable the calculation of dose, the tumour shapes
are assumed to be spherical, which is an obvious over-
simplification. The degree of MoAb binding will also vary
from patient to patient and will change with respect to the
time from injection. In four of the eight cases studied, we
have withdrawn small volumes of fluid from the Ommaya
reservoir 8 to 19 days after injecting the '31I-MoAb conjugate.
Counting this material and extrapolating to the whole
volume ofdistribution revealed a range ofbinding of 8-80%
of the injected dose. Using the dosimetry model above,
tumour doses of 110, 238, 236 and 3768 Gy for patients 1, 2,
3 (second injection) and 7 respectively would occur. Interest-
ingly, in each case studied, 13'I was largely attached to the
MoAb which also remained immunoreactive in in vitro
assays.
Rather than continuing escalating the dose of 131I-MoAb
given as a single injection, we are proposing to investigate
repeated therapy in patients with either tumour resection
cavities or cystic lesions. It is clear from our studies on the
intraventricular injection of MoAbs to patients with diffuse
leptomeningeal spread of tumour, that repeated injections of
mouse MoAbs will result in the generation of a systemic
anti-mouse Ig response. How this will affect the clearance of
MoAb from a cystic lesion or tumour cavity is not clear. No
effect was noted in patient 3, as clearance from the tumour
after the second injection was considerably longer than the
first. However, no systemic anti-mouse Ig response was noted
in this patient.
Following repeated intrathecal injections of '1I-MoAbs,
we have demonstrated that the anti-mouse Ig observed
systemically is not mirrored, to the same extent, within the
intrathecal compartment. This may also be the case for intra-
tumoral lesions. Alternatively, if the dosimetry presented here
is correct, the initial injection of '1'I-MoAb will certainly
cause tumour necrosis. This, in turn, might make the area
more 'leaky' and as a result enhance the loss of conjugate
from the injection site. Furthermore, the injection of MoAbs
into the tumour may cause an invasion of macrophages.
Such cells, through phagocytosis, could adversely affect the
residence time of MoAbs in the tumour site.
The purpose of this investigation was to undertake a pilot
study on the practicability of injecting radiolabelled MoAbs
into tumour cysts/cavities. Bearing in mind the aggressive
nature of the tumours being treated, it is unreasonable to
expect to see prolonged tumour responses from a single
injection of '3I-MoAb. However, it is clear from the two
patients with cystic lesions that responses to 13'1-MoAbs do
occur. To obtain accurate response data on patients having 131I-MoAbs after debulking surgery for relapsed disease
would require a study randomising patients to either receiv-
ing or not receiving antibody instillation. This, we believe, is
not the correct approach at the current time. More impor-
tant, is to establish the principles involved in repeat therapy
and explore the use of 90Y-MoAbs in this context. If results
from these preliminary studies are promising, we believe it
justifiable to initiate a study incorporating 9Y-MoAb
therapy into the primary treatment of patients with glioma.
Our projected plan would be to treat all patients with con-
ventional surgery and radiotherapy and subsequently ran-
domise the group to receive either 'Y-MoAb or no therapy.
Whilst this is a long way from the original concept of using
MoAbs as targeting agents, it may prove to be one of the
ways in which they can be exploited most successfully.31I-MoAb FOR TREATMENT OF MALIGNANT GLIOMAS 151
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